<DOC>
	<DOCNO>NCT01840410</DOCNO>
	<brief_summary>This study conduct evaluate efficacy safety 0.5 mg ranibizumab adult adolescent patient visual impairment due choridal neovascularization ( CNV ) .</brief_summary>
	<brief_title>Assess Efficacy/Safety Intravitreal Ranibizumab Patients With Vision Loss Due Choroidal Neovascularization .</brief_title>
	<detailed_description />
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Key Diagnosis active CNV secondary cause CNV sequelae affect fovea ; BCVA must ≥ 24 ≤ 83 letter study eye ; Visual loss study eye mainly due presence eligible type CNV ; Key Women childbearing potential ; Active malignancy ; History stroke less 6 month prior screen ; Uncontrolled systemic inflammation infection ; Active diabetic retinopathy , active ocular/periocular infectious disease active severe intraocular inflammation ; CNV condition high likelihood spontaneous resolution ; History intravitreal treatment steroid ; History laser photocoagulation ; History intraocular treatment antiangiogenic drug .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Vision Impairment</keyword>
	<keyword>Abnormal growth blood vessel</keyword>
</DOC>